How AI Transforms Regulatory Submission: Current Clinical Implementation and Future Prospects

Abstract

Artificial Intelligence (AI) is transforming drug development and regulatory submission by enabling advanced data analytics, predictive modeling and intelligent decision support systems. Beyond efficiency gains, AI establishes a translational bridge between model-informed drug development (MIDD) and clinical implementation, turning regulatory evidence into actionable insights that enhance therapeutic precision and patient outcomes. This perspective paper explores AI's current applications, regulatory integrations, and future prospects in accelerating data-driven, patient-centered drug development.